Magnesium Sulfate for Severe Preeclampsia: When the Level Looks Fine but the Patient Does Not
Ms. Okafor, 34, G2P1 at 35 weeks 4 days, was admitted 18 hours ago with severe preeclampsia. She is receiving magnesium sulfate 2 g/hour IV after a 4 g loading dose, plus labetalol 200 mg by mouth twice daily. At 1400 her blood pressure is 172/106, repeating 168/102; heart rate 92; respiratory rate 10; SpO2 96% on room air; urine output 20 mL/hour over the past 2 hours via Foley catheter. Deep tendon reflexes are 1+ and sluggish. She answers questions slowly, drifts off mid-sentence, and rouses to voice. She reports blurred vision and a frontal headache rated 6/10. The fetal heart rate is 148/min with minimal variability and no decelerations over the last 20 minutes. The most recent magnesium level is 6.4 mEq/L (laboratory therapeutic range 4-7 mEq/L). The charge nurse asks whether she can cover the room while the primary nurse takes a break.
1. Interpret the reflex, respiratory, urine output, and sedation findings. Which are expected effects of magnesium therapy and which signal toxicity? State the immediate actions and their rationale.
Read the worked answer
Expected effects of therapeutic magnesium include flushing and warmth, mild drowsiness, and reflexes that remain present. These findings are not expected at a therapeutic dose: reflexes that are 1+ and sluggish (loss of deep tendon reflexes is the earliest sign of toxicity), a respiratory rate of 10, urine output of 20 mL/hour, and sedation deep enough that she drifts off mid-sentence.
The mechanism matters: magnesium is cleared almost entirely by the kidney, so oliguria causes accumulation even at a constant infusion rate. Respiratory depression follows loss of reflexes, and cardiac conduction changes come after that.
Actions: stop the magnesium infusion immediately and do not restart it without an order; call the provider and activate rapid response; place on continuous pulse oximetry and cardiac monitoring; verify the IV site and draw a repeat magnesium level from a site other than the infusion line; keep calcium gluconate 1 g IV (10 mL of 10% solution) available and give it as ordered for symptomatic toxicity; monitor reflexes, respiratory rate, urine output, and level of consciousness hourly; notify the provider of the BP 172/106, which also needs treatment.
2. The magnesium level is 6.4 mEq/L, inside the stated therapeutic range. How do you reconcile that with your assessment?
Read the worked answer
By treating the patient, not the number. Three points explain the gap. First, serum magnesium reflects the extracellular compartment and lags behind tissue effect, so a level drawn hours ago may not represent the current infusion burden - especially with oliguria, where the drug accumulates between draws. Second, the quoted 4-7 mEq/L range is a population reference for prophylaxis; individual tolerance varies, and a client with a level of 6.4 and hyporeflexia, bradypnea, and sedation is clinically toxic regardless. Third, sampling error is real - a level drawn above or near the infusion port can read falsely high or low, so the specimen source must be verified and repeated from a distal site.
The nursing conclusion: the clinical findings take precedence. Documentation should record the objective signs, the exact time the infusion was stopped, the provider notification, and the calcium gluconate availability. A level inside the reference range is reassuring only when the assessment is also reassuring.
3. The fetal heart rate shows minimal variability with a normal baseline and no decelerations. What are the possible causes, and what is the priority nursing action?
Read the worked answer
Minimal variability is a fetal neurologic finding, not automatically hypoxia. Possible causes here: magnesium sulfate itself, which commonly dampens variability; fetal immaturity at 35 weeks; a fetal sleep cycle (usually 20-40 minutes); uteroplacental insufficiency from severe preeclampsia; maternal hypotension, hypoxia, or a drug effect; and rarely a pre-existing fetal condition.
There are no decelerations and the baseline is normal, so this is not an indication for emergent delivery by itself - but it must not be dismissed either. Priority action: correct maternal contributors first. Recheck maternal blood pressure, SpO2, and the magnesium infusion status, reposition to a left lateral tilt, give oxygen if SpO2 is low, ensure IV access, and continue continuous monitoring while notifying the provider. Then reassess: if variability improves with a fetal sleep cycle or after maternal correction, this supports a benign explanation; if it persists with a rising baseline, late decelerations, or a nonreassuring biophysical profile, the provider may move toward delivery. The nursing judgment is to act on reversible maternal factors and escalate with data, not to wait passively for a deceleration.